Showing results (191-200 of 212) with videos related to

Sort By:
Pageof 22
Lancet (London, England)|May 30, 2026
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trialGeorg Lenz, Marek Trněný, John M Burke, et al.
The Lancet. Oncology|January 14, 2022
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trialYoon-Koo Kang, Li-Tzong Chen, Min-Hee Ryu, et al.
Leukemia & Lymphoma|August 20, 2025
Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapyElżbieta Iskierka-Jażdżewska, Won Seog Kim, Seok-Goo Cho, et al.
Cancer Communications (London, England)|October 18, 2019
Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) studySung Yong Oh, Won Seog Kim, Jin Seok Kim, et al.
International Journal of Hematology|October 16, 2012
Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL)Sung Yong Oh, Won Seog Kim, Jin Seok Kim, et al.
Cancer Science|September 14, 2010
Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) studySung Yong Oh, Won Seog Kim, Jin Seok Kim, et al.
Cancer Research and Treatment|September 2, 2015
A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and HistologyJun Ho Yi, Jung Hun Kang, In Gyu Hwang, et al.
Leukemia & Lymphoma|July 22, 2014
Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of LymphomaGyeong-Won Lee, Se-Il Go, Seok-Hyun Kim, et al.
Journal of Hematology & Oncology|August 15, 2012
Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)Yu Ri Kim, Jin Seok Kim, Yoo Hong Min, et al.
The Oncologist|September 8, 2019
A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin ToxicitiesYoung Saing Kim, Jun Ho Ji, Sung Yong Oh, et al.
Pageof 22